2023 Amplifier TX AB
amplifier-tx.com
Actively hiring
Financial Services
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
11-50
employees, estimated range
Backers
2
RA Capital Management, Future Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management 
Future Ventures Similar startupsby what they do, their industry and backers
Advanced medical devices for the treatment of metabolic diseases.
Developer of breakthrough biotherapeutics for B cell cancers, metabolic diseases, and chronic hepatitis B infections.
Astonished? Contact Us Email [email protected] full name* email address* message* Thank you for submitting the form.
At Twin, we combine advanced medical science with digital twin technology to help people reverse, improve, and prevent chronic metabolic…
About Us NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes…
We are on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases.
Overview
Harnessing the potential of AMPK activation to address metabolic disease. Read More >.
News
Join Us at ENDO 2025
Join us in San Francisco, CA, July 12-15, 2025, for ENDO 2025 at the Moscone Convention Center. With over 7,000 attendees, nearly 2,500 abstracts and over 200 other sessions, ENDO is the leading global meeting on endocrinology research and clinical care.
Read more
Report
Biomedicine & Pharmacotherapy May 14, 2024 The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury Acute kidney injury (AKI) disrupts energy metabolism, and targeting this pathway through AMP-activated protein kinase (AMPK) may offer protection. This study evaluates ATX-304, a pan-AMPK activator, in both C57Bl6 mice and tubular epithelial cell (TEC) cultures. Results show that ATX-304 effectively activates AMPK, reduces markers of kidney injury, and enh
Acute kidney injury (AKI) disrupts energy metabolism, and targeting this pathway through AMP-activated protein kinase (AMPK) may offer protection. This study evaluates ATX-304, a pan-AMPK activator, in both C57Bl6 mice and tubular epithelial cell (TEC) cu
Read more
Report
O304 ameliorates hyperglycemia in mice by dually promoting muscle glucose effectiveness and preserving β-cell function
Although insulin mediated glucose uptake in skeletal muscle is a major mechanism ensuring glucose disposal in humans, glucose effectiveness, i.e., the ability of glucose itself to stimulate its own uptake independent of insulin, accounts for roughly half
Read more
Report
Ageing Research Reviews April 12, 2016 Age-related changes in AMPK activation: Role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways This review article provides an overview of the various upstream processes that either activate or inhibit the AMPK signaling responsiveness, but also the many age-related changes can potentially suppress AMPK activation. Visit
This review article provides an overview of the various upstream processes that either activate or inhibit the AMPK signaling responsiveness, but also the many age-related changes can potentially suppress AMPK activation.
Read more
Report